Le Lézard
Classified in: Health
Subjects: PDT, WOM

ConTIPI Medical Launches a New Website Highlighting Nonsurgical Devices for Pelvic Floor Disorders


CAESAREA, Israel, May 24, 2018 /PRNewswire/ --  ConTIPI Medical, an Israeli Medical device company, provides non-surgical and disposable vaginal solutions for women with various Pelvic Floor Disorders (PFD's). ConTIPI Medical's vaginal solutions follow a specific concept allowing women to manage their condition directly. This concept has already proved itself, brought from a design into a mature product in the market. The Impressa Device for Stress Urinary Incontinence, bought by Kimberly Clark Worldwide Inc, is marketed by Kimberly Clark Inc. under its Poise® brand (http://www.impressapro.com). ConTIPI Medical's second product, the ProVate Device, intended for the non-surgical management of Pelvic Organ Prolapse (POP) has a CE Mark for marketing in the EU and is currently within final clinical studies in the USA (considered an investigational device, limited by Federal law to investigational use).

Dr. Elan Ziv, MD, OBGYN, FPMRS, CEO & Medical Director of ConTIPI Medical

Each device comes ready for use within a wrapper, to be used by the user herself in the comfort of her home. The devices are inserted vaginally, compressed to small dimensions inside an applicator. Within the vagina, the applicator deploys the device and it opens to provide support to pre-defined specific sites along the vaginal walls. At the end of usage, the device is removed by a pull of a string, which also causes it to considerably diminish in size, and is disposed. Such devices allow women to take control over their medical problem and use them in privacy and at their convenience.

Impressa device: The Impressa device was invented by a urogynecologist in order to bridge the large gap between non-invasive and invasive treatments for Stress Urinary Incontinence in women. The device was designed to be a user friendly, disposable vaginal support, available to many women, including those who do not wish to disclose their intimate problem.  The device is available over-the-counter.

ProVate device: Most women with Pelvic Organ Prolapse will only require non-invasive management. Existing pessaries are associated with high discontinuation rate, and with high rate of reluctance to use a reusable device which is difficult for most users to insert and remove. The ProVate disposable device was designed to provide vaginal support, inserted and removed by the user at her home.

ConTIPI Medical intends to develop more solutions for other Pelvic Floor Disorders in women, following its unique design concept.

ConTIPI Medical is spearheaded by a strong management team with extensive experience and proven ability to bring a product from concept to market, and is backed by well-known consultants, in Israel and abroad. As a dedicated Research and Development (R&D) company, the entire product development process is conducted within the company.

The company's management includes Dr. Elan Ziv, MD, OBGYN, FPMRS, (CEO & Medical Director); Meital Vaknin-Shimony, B.Sc., MBA, (VP Operations) and Zohar Tyroler, B.Sc., MBA, (VP Research & Development).

ConTIPI Medical is currently launching a new website. Site address: www.contipi.com

Contact: Hofit Shalev, [email protected] 

 

SOURCE ConTIPI Medical


These press releases may also interest you

at 17:00
StateHouse Holdings Inc. ("StateHouse" or the "Company") , a California-focused, vertically integrated cannabis company, today announced further to its press release dated April 15, 2024, that the Ontario Securities Commission (the "OSC") has denied...

at 16:42
Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announces the filing of its Annual Report on Form 20-F for the fiscal year ended December 31,...

at 16:27
Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Thursday, the FDA posted a safety communication to inform the public and healthcare providers that the agency has required and...

at 16:19
Unifor expects to achieve the wage increases and benefit improvements awarded to Ontario OCHU-CUPE and SEIU Healthcare members by Arbitrator William Kaplan in a recent decision....

at 16:10
Acadia Pharmaceuticals Inc. today announced that on April 10, 2024, the Compensation Committee of Acadia's Board of Directors (the "Committee") granted inducement awards consisting of non-qualified stock options to purchase 21,659 shares of common...

at 16:10
Calidi Biotherapeutics, Inc. , a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the closing of its previously announced public offering of 15,197,500 shares of common stock (or pre-funded...



News published on and distributed by: